Effectiveness of ethanolamine oleate as a pleural sclerosing agent in rabbits.
The ideal pleural sclerosing agent should be easily administered, without significant side effects, inexpensive, and widely available. None of the agents presently used meets all of these criteria. Ethanolamine oleate (ETH) is a sclerosing agent used in the sclerotherapy treatment of varicose veins of the legs and esophagus. The objective of the present study was to assess the efficacy of ETH as a pleural sclerosant in rabbits. An additional objective was to assess if better results were obtained when dextrose 50% (D50) as opposed to saline was used as the diluent. Each group of 10 rabbits received a total volume of 2 ml intrapleurally. The eight treatments were as follows: (1) 2 ml saline; (2) 2 ml D50; (3) 25 mg ETH plus 1.5 ml saline; (4) 25 mg ETH plus 1.5 ml D50; (5) 50 mg ETH plus 1.0 ml saline; (6) 50 mg ETH plus 1 ml D50; (7) 75 mg ETH plus 0.5 ml D50, and (8) 100 mg ETH. The rabbits were sacrificed 28 days after the injection. The intrapleural instillation of ETH resulted in evident pleurodesis, which was dose-dependent; 100 mg ETH induced significantly (p<0.05) more adhesions than did any other treatment. The selection of the diluent had no effect on the pleurodesis. The microscopic examination of the right visceral pleura showed that the mean degree of fibrosis after 100 mg ETH was significantly (p<0.05) greater than that after the other solutions. The mean degree of pleural inflammation, lung inflammation and lung fibrosis was minimal in all the groups. From this study we conclude that undiluted ETH produces pleurodesis in our experimental model. At the doses used, the pleurodesis was less than that produced after talc, tetracycline derivatives or silver nitrate in the same model.
Teixeira
L R
LR
Instituto do Coracao, Faculty of Medicine, University of São Paulo, Brazil; Department of Medicine, University of Săo Paulo, Brazil.
Vargas
F S
FS
Carmo
A O
AO
Silva
L M
LM
Marchi
E
E
Light
R W
RW
D000704:Analysis of Variance; D000818:Animals; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D019856:Ethanolamine / Q000008:administration & dosage*; D008297:Male; D010994:Pleura / Q000187:drug effects; D010996:Pleural Effusion / Q000628:therapy*; D018700:Pleurodesis / Q000379:methods*; D011030:Pneumothorax / Q000628:therapy*; D011817:Rabbits; D012016:Reference Values; D012597:Sclerosing Solutions / Q000008:administration & dosage*; D018709:Statistics, Nonparametric
D012597:Sclerosing Solutions; D019856:Ethanolamine